Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mezagitamab in late antibody-mediated rejection after kidney transplantation
jRCT2071260091Phase 2Not yet recruiting
- Sponsor
- Takeda
- Start
- Oct 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 2, randomised, double-blind trial in humoral rejection comparing Mezagitamab + Placebo, Mezagitamab and Placebo (3 arms). Primary endpoints: Number of participants with treatment-emergent adverse events, Number of participants with related treatment-emergent adverse events and 4 more. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
mezagitamab
03
Conditions
humoral rejection
Beyond the preview
Go deeper on jRCT2071260091.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071260091.